Tag: idera pharmaceuticals

Idera Pharmaceuticals Provides 2020 Update and Outlook

Idera Pharmaceuticals is providing an update on its tilsotolimod clinical development program and a corporate outlook for 2020.

Idera Confirms Private Placement of up to US$97.7 Million

Idera Pharmaceuticals announced today it is entering into an agreement for gross proceeds of US$3.9 million.

Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial

Idera Pharmaceuticals  (NASDAQ:IDRA) is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered...

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.

Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125

Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology...

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.

5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top

Second Sight, Juniper, Athersys, Aptose and ArQule were last week's five top-gaining NASDAQ biotech stocks. See what moved their share...